Wuxi AppTec Co (Wuxi AppTec Co) ROCE % : 15.14% (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Wuxi AppTec Co ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Wuxi AppTec Co's annualized ROCE % for the quarter that ended in Dec. 2023 was 15.14%.

Wuxi AppTec Co ROCE % Historical Data

The historical data trend for Wuxi AppTec Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Wuxi AppTec Co ROCE % Chart

Wuxi AppTec Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

11.62

12.00

15.45

22.38

21.80

Wuxi AppTec Co Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															15.39	20.86	28.57	25.01	15.14

Wuxi AppTec Co ROCE % Calculation

Wuxi AppTec Co's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	1684.207	/	( ( (9278.989 - 2079.746)	+	(10317.547 - 2066.65) )	/ 2 )
	=	1684.207	/	( (7199.243	+	8250.897)	/ 2 )
	=	1684.207	/	7725.07
	=	21.80 %

Wuxi AppTec Co's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	1193.052	/	( ( (9832.867 - 2326.578)	+	(10317.547 - 2066.65) )	/ 2 )
	=	1193.052	/	( ( 7506.289	+	8250.897 )	/ 2 )
	=	1193.052	/	7878.593
	=	15.14 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Wuxi AppTec Co (OTCPK:WUXIF) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Wuxi AppTec Co ROCE % Related Terms

Thank you for viewing the detailed overview of Wuxi AppTec Co's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Wuxi AppTec Co (Wuxi AppTec Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Wuxi AppTec Co Ltd (OTCPK:WUXIF) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

WUXAY:USA 02359:Hong Kong WX8:Germany 603259:China

Address

288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai, CHN, 200131

Website

https://www.wuxiapptec.com

Wuxi AppTec Co Ltd provides a portfolio of research and manufacturing services through the discovery, development, and manufacturing spectrum for small-molecule drugs, cell therapies, and gene therapies as well as providing testing services for medical devices. Its segments comprise China-based laboratory services; U.S.-based laboratory services; Clinical research and other CRO services; CDMO services; and Others. The majority of revenue gets derived from China-based laboratory services that include small molecules discovery, such as synthetic chemistry, medicinal chemistry, analytical chemistry, biology, drug metabolism and pharmacokinetics (DMPK)/absorption, distribution, metabolism, and excretion (ADME), toxicology and bioanalytical services.